Technical advances are ushering in a new era for companion diagnostics. What does Pharma need know? The introduction of liquid biopsies and advances in next generation sequencing are just the latest developments driving...

Ensuring payer support, delivering stakeholder benefit and generating commercial returns: Pharma's growing orphan drug challenge Rising competition and closer scrutiny by hard-pressed payers are just two of the trends...

Can nanomedicines really offer pharma a compelling alternative approach to precision medicines? Delivering accurate diagnosis for clinicians, safer medicines for patients and lower costs through reduced waste and costly...

Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...

How can medical affairs capability be enhanced to unlock the Brazilian, Russian, Indian and Chinese pharma markets? The pharma markets of Brazil, Russia, India and China (BRIC) are becoming increasingly complex with...

Are you convinced your MSL teams are keeping up with evolving market practice? The best medical science liaison (MSL) teams have made significant changes to adapt to a whole new world. The pharma companies getting the...

Sales numbers are no longer the gold standard for measuring commercial success. What is? The maturing key account management (KAM) model has transformed the way customer-facing teams operate: the challenge now is to use...

When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...